BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia - PubMed (original) (raw)
. 2006 Apr 15;176(8):5108-16.
doi: 10.4049/jimmunol.176.8.5108.
Delphine Rea, Vannary Tieng, Nicolas Dulphy, Manuel Brun, Jean-Michel Cayuela, Philippe Rousselot, Ryad Tamouza, Philippe Le Bouteiller, François-Xavier Mahon, Alexander Steinle, Dominique Charron, Hervé Dombret, Antoine Toubert
Affiliations
- PMID: 16585609
- DOI: 10.4049/jimmunol.176.8.5108
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia
Nicolas Boissel et al. J Immunol. 2006.
Abstract
MHC class I chain-related molecules (MIC) participate in immune surveillance of cancer through engagement of the NKG2D-activating receptor on NK and T cells. Decreased NKG2D expression and function upon chronic exposure to NKG2D ligands and/or soluble forms of MIC (sMIC) may participate in immune escape. In chronic myeloid leukemia, a malignancy caused by the BCR/ABL fusion oncoprotein, we showed cell surface expression of MICA on leukemic, but not healthy, donor hemopoietic CD34+ cells. At diagnosis, chronic myeloid leukemia patients had abnormally high serum levels of sMICA and weak NKG2D expression on NK and CD8+ T cells, which were restored by imatinib mesylate (IM) therapy. In the BCR/ABL+ cell line K562, IM decreased both surface MICA/B expression and NKG2D-mediated lysis by NK cells. Silencing BCR/ABL gene expression directly evidenced its role in the control of MICA expression. IM did not affect MICA mRNA levels, but decreased MICA protein production and release. Sucrose density gradient fractionation of K562 cytoplasmic extracts treated with IM showed a shift in the distribution of MICA mRNA from the polysomal toward the monosomal fractions, consistent with decreased translation. Among the major pathways activated by BCR/ABL that regulate translation, PI3K and mammalian target of rapamycin were shown to control MICA expression. These data provide evidence for direct control of MICA expression by an oncogene in human malignancy and indicate that posttranscriptional mechanisms may participate in the regulation of MICA expression.
Similar articles
- The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
Cebo C, Da Rocha S, Wittnebel S, Turhan AG, Abdelali J, Caillat-Zucman S, Bourhis JH, Chouaib S, Caignard A. Cebo C, et al. J Immunol. 2006 Jan 15;176(2):864-72. doi: 10.4049/jimmunol.176.2.864. J Immunol. 2006. PMID: 16393970 - The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M. Salih J, et al. Int J Cancer. 2010 Nov 1;127(9):2119-28. doi: 10.1002/ijc.25233. Int J Cancer. 2010. PMID: 20143399 - Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A. Burchert A, et al. Leukemia. 2005 Oct;19(10):1774-82. doi: 10.1038/sj.leu.2403898. Leukemia. 2005. PMID: 16136169 - Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
Machuldova A, Holubova M, Caputo VS, Cedikova M, Jindra P, Houdova L, Pitule P. Machuldova A, et al. Front Immunol. 2021 Mar 30;12:651751. doi: 10.3389/fimmu.2021.651751. eCollection 2021. Front Immunol. 2021. PMID: 33868289 Free PMC article. Review. - MICA and MICB genes: can the enigma of their polymorphism be resolved?
Stephens HA. Stephens HA. Trends Immunol. 2001 Jul;22(7):378-85. doi: 10.1016/s1471-4906(01)01960-3. Trends Immunol. 2001. PMID: 11429322 Review.
Cited by
- The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.
Textor S, Bossler F, Henrich KO, Gartlgruber M, Pollmann J, Fiegler N, Arnold A, Westermann F, Waldburger N, Breuhahn K, Golfier S, Witzens-Harig M, Cerwenka A. Textor S, et al. Oncoimmunology. 2016 Jul 28;5(7):e1116674. doi: 10.1080/2162402X.2015.1116674. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622013 Free PMC article. - Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.
Sanchez CJ, Le Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D, Costello RT. Sanchez CJ, et al. Cancer Immunol Immunother. 2011 Jan;60(1):1-13. doi: 10.1007/s00262-010-0898-x. Epub 2010 Aug 10. Cancer Immunol Immunother. 2011. PMID: 20697893 Free PMC article. Review. - Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands.
Fernández-Messina L, Ashiru O, Boutet P, Agüera-González S, Skepper JN, Reyburn HT, Valés-Gómez M. Fernández-Messina L, et al. J Biol Chem. 2010 Mar 19;285(12):8543-51. doi: 10.1074/jbc.M109.045906. Epub 2010 Jan 14. J Biol Chem. 2010. PMID: 20080967 Free PMC article. - MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.
Okita R, Yukawa T, Nojima Y, Maeda A, Saisho S, Shimizu K, Nakata M. Okita R, et al. Cancer Immunol Immunother. 2016 May;65(5):499-509. doi: 10.1007/s00262-016-1814-9. Epub 2016 Mar 3. Cancer Immunol Immunother. 2016. PMID: 26940474 Free PMC article. - Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.
Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L, Bruno B. Pittari G, et al. Front Immunol. 2017 Nov 7;8:1444. doi: 10.3389/fimmu.2017.01444. eCollection 2017. Front Immunol. 2017. PMID: 29163516 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous